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Abstract
Vasomotor symptoms, particularly hot flushes (HFs), are the most frequently reported 
symptom by menopausal women. In particular, for young women diagnosed with breast 
cancer, who experience premature ovarian failure due to cancer treatments, severe HFs 
are an unsolved problem that strongly impacts on quality of life. The optimal manage-
ment of HFs requires a personalised approach to identify the treatment with the best 
benefit/risk profile for each woman. Hormonal replacement therapy (HRT) is effective 
in managing HFs but it is contraindicated in women with previous hormone-dependent 
cancer. Moreover, many healthy women are reluctant to take HRT and prefer to manage 
symptoms with non-hormonal strategies. In this narrative review, we provide an update 
on the current available non-oestrogenic strategies for HFs management for women who 
cannot, or do not wish to, take oestrogens. Since isoflavones have oestrogenic properties 
and it is not known if they can be safely consumed by women with previous hormone-
dependent cancer, they were excluded. Selective serotonin reuptake inhibitors/selective 
serotonin-norepinephrine reuptake inhibitors, as well as other neuroactive agents, some 
herbal remedies and behavioural strategies are considered.
Keywords: vasomotor symptoms, hot flushes, menopause, non-oestrogenic therapies, non-
hormonal therapies
Introduction
Hot flushes (HFs) are the most bothersome menopause-related symptom, affecting up 
to 85% of menopausal women with various severity, frequency and duration [1, 2]. They 
first begin during the menopausal transition and they last around 7–10 years, although it 
is reported that some women can experience HFs for longer periods of time [3, 4]. Hor-
mone replacement therapy (HRT) is considered the most effective treatment, but it is not 
indicated for all patients, such as for those with a personal history of hormone-dependent 
cancer or of venous thromboembolism [5, 6].
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In particular, for young women diagnosed with breast cancer, who experience premature ovarian failure due to cancer treatments, severe 
HFs are an unsolved problem that strongly impacts on quality of life [7]. Nowadays, for hormone-dependent tumours in high-risk patients, 
extended therapy with adjuvant antihormonal treatment up to 10 years is suggested and for premenopausal women, the combination of 
ovarian suppression plus aromatase inhibitors should be considered [8] with consequent negative influence on climacteric symptoms [9].
Moreover, many women with no contraindication to HRT refuse hormonal treatment. In particular, after the publication of the Women’s 
Health Initiative (WHI) randomised trial in 2003, a progressive reduction in HRT prescription happened worldwide because HRT emerged as 
a potential risk factor for breast cancer [10]. Physicians are often reluctant in prescribing HRT for this reason, and nowadays, two-thirds of 
healthy women who seek treatment for menopausal symptoms will not be treated with HRT [5].
As a consequence, a spread of non-hormonal therapies is observed: data from different surveys show that around 30%–80% of women with 
HFs employ non-hormonal treatments [11–13]. The prevalence of complementary and alternative medicine (CAM) therapies is increasing as 
showed by the Study of Women’s Health Across the Nation, being 48.5% in 2002 and 80% in 2008 [11]. Moreover, data from surveys show 
that women prefer CAM to conventional therapies because they consider CAM natural and safe, having a positive effect on maintaining good 
general health and having no or mild side effects. However, women often do not inform physicians about their decision to start using CAM 
since they feel that healthcare providers (HCPs) lack knowledge about it and prefer to receive information from different sources (media, 
friends and relatives) [12–14].
For these reasons, it is important that HCPs are to be well informed about alternative remedies for menopausal symptoms. 
Moreover, when discussing non-oestrogenic alternatives for menopausal symptoms, we have to keep in mind the placebo effect. Throughout 
the literature, the placebo effect is reported in up to 59% of the different studies on menopausal treatment. For this reason, a result which is 
similar to that achieved by placebo must be a good one, even if it is not significant. Moreover, menopause is a complex period of life where 
many physical and psychological changes interact, determining a higher susceptibility to the relationship between the woman and HCPs [14].
In this narrative review, we provide an update on the available non-oestrogenic alternatives for HFs treatment in patients who do not wish 
to or cannot employ HRT.
We searched through PubMed articles in an interval period (2000–2017) using the following keywords: menopause, hot flushes, climacteric 
symptoms, vasomotor symptoms, non-hormonal treatment. Only the publications written in English were included. 
As in a narrative review, we summarised evidence from randomised controlled trials (RCTs) about non-oestrogenic alternatives for meno-
pause-related HFs in order to broaden HCPs’ knowledge on the topic. Since isoflavones have oestrogenic properties and it is not known if 
they can be safely consumed by women with previous hormone-dependent cancer, they were excluded from this review. Thus, the present 
review merely reflects the expert opinion of the authors on addressing the various non-oestrogenic strategies to manage vasomotor meno-
pausal symptoms and their appropriate application on a patient-by-patient basis. 
Management of vasomotor menopausal symptoms with non-hormonal strategies
Selective serotonin reuptake inhibitors and selective serotonin-norepinephrine reuptake inhibitors
Selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs) are effective non-hormonal 
alternatives for vasomotor symptoms [15], reducing HFs intensity and frequency in percentages ranging from 20% to 65% [15–18].
Since HFs are thought to occur due to the changes in thermoregulation induced by oestrogen deprivation, with a consequent decrease in 
serotonin levels [19], the block of serotonin and norepinephrine receptors induced by SSRIs and SNRIs may oppose this imbalance. 
Even if many studies have assessed the efficacy of SSRIs and SNRIs in reducing HFs [15], paroxetine salt 7.5 mg/day is the only officially Food 
and Drug Administration (FDA)-approved product for the treatment of moderate-to-severe vasomotor symptoms in menopausal women [20].
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Among SSRIs, paroxetine, sertraline, fluoxetine and escitalopram have been studied for HFs in menopausal women, with most of the studies 
reporting positive results (Table 1). As regards SNRIs, duloxetine, venlafaxine and its active metabolite O-desmethylvenlafaxine have also 
shown a benefit in HF reduction (Table 2).
Table 1. SSRIs for HFs.
Type of drug and dose Effectiveness Side effects Interactions with tamoxifen 
Paroxetine 10–25 mg/day 
(7.5 mg salt is the only SSRIs/
SNRIs approved for the treatment 
of menopausal moderate-to-severe 
HFs by FDA) 
(first-line option for HFs)
[15, 16, 17, 21, 23]
Up to 64% HFs score reduction, 
improvement also of sleep
- Nausea at the 20 mg dose 
- The low dosage has less toxicity 
-  low withdrawal rate, in particular, 
with low doses
Potent inhibitors of CYP2D6 
enzyme; they should be avoided 
during tamoxifen use
Fluoxetine 10–30 mg/day
(second-line option for HFs)
[16, 17, 21, 22]
24% HFs score and 19% HFs fre-
quency reduction
- 18% withdrawal rate
-  withdrawal due to more ineffec-
tiveness of treatment rather than to 
side effects
Sertraline 25–100 mg/day
(second-line option for HFs)
[16, 17, 21]
Modest effect on HFs - 10% dropout rate 
-  nausea and decreased sexual 
function
Moderate effect on the CYP2D6 
enzyme
Citalopram 10–20 mg/day
(first-line option for HFs) [16, 17]
Up to 49%–55% HFs score 
reduction
- 20% withdrawal rate
Mild inhibitory effect on the 
CYP2D6 enzyme; they can be used 
in tamoxifen users
Escitalopram 10–20 mg/day
(first-line option for HFs)
[16, 17]
47% HFs frequency and 24% 
reduction
- Best tolerability profile 
- withdrawal rate of 4%
- nausea, weakness and drowsiness
SSRIs = selective serotonin reuptake inhibitors; SNRIs = selective serotonin-norepinephrine reuptake inhibitors; FDA = Food and Drug Administration;  
HFs = hot flushes 
Table 2. SNRIs for HFs.
Type of drug and dose Effectiveness Side effects Interaction with tamoxifen
Duloxetine 
30–120 mg/day
(first-line option for HFs) [16]
56% HFs frequency and 62% HFs 
score reduction
Nausea, weakness, drowsiness, 
insomnia, mouth dryness and 
constipation
Moderate effect on the CYP2D6 
enzyme
Venlafaxine 
37.5–150 mg/day
(first-line option for HFs)
[16, 17, 21, 24, 25]
Immediate effect and strong  
HFs reduction, up to 30%–58% 
reduction in HFs frequency and 
37%–61% in the HFs score
Nausea, constipation,
dry mouth, headache,
sleeplessness and decreased 
appetite Low inhibitory effect on the 
CYP2D6 enzyme; they are the safest 
choices in tamoxifen usersDesvenlafaxine 
100–150 mg/day
(first-line option for HFs)
[15, 16, 17, 21]
60%–66% HFs frequency and 24%–
29% HFs severity reduction, already 
in the first week of treatment
Only in the first week of treatment 
(nausea, dizziness and headache)
SNRIs = selective serotonin-norepinephrine reuptake inhibitors; HFs = hot flushes
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In breast cancer patients, SSRIs and SNRIs are proven to have a mild to moderate effect in reducing HFs, as assessed in a Cochrane Review 
on the efficacy of non-hormonal therapies for HFs in breast cancer survivors, including six RCTs on SSRIs/SNRIs (venlafaxine, paroxetine, 
fluoxetine and sertraline) conducted in 451 women [21].
In particular, as regards the use of SSRIs for treating HFs in breast cancer patients (Table 1), the double-blinded RCT by Loprinzi et al [22] 
showed that fluoxetine 20 mg/day was well tolerated and determined a significant but modest decrease in HFs’ score in 68 women, after 8 
weeks of treatment.
Paroxetine, both the dose of 10 mg and 20 mg/day was evaluated in the RCT by Stearns et al [23] on 107 women with or without a history 
of breast cancer, of which more than 80% were breast cancer survivors mainly under tamoxifen. Both doses significantly decreased HFs, but 
the lower dose was less discontinued by women and even significantly improved sleep compared to placebo.
As regards SNRIs use for HFs in breast cancer survivors (Table 2), most studies focussed on venlafaxine [24, 25]. In the RCT by Loprinzi et 
al [24], 191 patients with or without previous breast cancer received placebo or venlafaxine at three different doses (37.5 mg, 75 mg and 
150 mg/day). After week 4 of treatment, HFs severity decreased from baseline by 27%, 37%, 61% and 61%, respectively in the four groups, 
with significant results. Side effects (xerostomia, decreased appetite, nausea and constipation) were significantly more frequently reported 
in the venlafaxine 75 mg and 150 mg groups than in the placebo group. In the double-blind, placebo-controlled RCT by Boeckhout et al [25], 
venlafaxine 75 mg for 12 weeks significantly decreased by 41% HFs score in 38 breast cancer survivors (p < 0.001) compared to 17 patients 
who received placebo. The decrease in HFs score in the venlafaxine group was evident very soon, in 42% of cases as early as after 4 weeks of 
treatment (p < 0.01, compared to placebo). Interestingly, in the same study, a relevant placebo effect was seen (29% at 12 weeks, compared 
to baseline, p < 0.001). In the venlafaxine group, the more frequently reported side effects were nausea, constipation and severe appetite 
loss.
That being so, the American Cancer Society (ACS) and the American Society of Clinical Oncology (ASCO) recommend that primary care clini-
cians should offer SSRIs and SNRIs for HFs relief in breast cancer survivors [9].
SSRIs and SNRIs act rapidly, with a decrease in vasomotor symptoms as early as after 2 weeks of treatment [17]. Among SSRIs and SNRIs, 
paroxetine, citalopram and escitalopram carry the best safety profiles [16]. The more frequently reported side effects are nausea, asthenia, 
dizziness, xerostomia, constipation and sexual dysfunction [15]. SNRIs can increase blood pressure; therefore, this variable should be moni-
tored in all patients [16].
Side effects, in combination with the fear of pharmacological interactions, may lead to early interruption of SSRIs/SNRIs treatment, with high 
dropout rates reported in the literature (up to 50% at 3 months) [26]. 
Due to the fast action in 2 weeks and to the safe tolerability profile, venlafaxine has been the more widely used antidepressant for HFs in 
clinical practice for many years. Nowadays, escitalopram is also prescribed as a first-line option for menopausal HFs. Indeed, due to its favour-
able tolerability profile, it is considered the antidepressant with the highest number of days of uninterrupted treatment, the best adherence to 
treatment and the lowest proportion of switching to other drugs [16, 26, 27].
For women with breast cancer, potential interference of antidepressants with tamoxifen has been reported since some SSRIs and SNRIs 
can inhibit CYP2D6 enzyme with a consequent decrease in the formation of the active metabolite from inactive tamoxifen. Among SSRIs, 
paroxetine and fluoxetine are the most potent inhibitors and they should be avoided during tamoxifen use; on the contrary, citalopram and 
escitalopram only have a limited inhibitory effect and can be used in tamoxifen users (Table 1). Among SNRIs, venlafaxine and desvenlafaxine 
are the safest choices while using tamoxifen [16] (Table 2).
Absolute contraindications to SSRIs and SNRIs use include previous neuroleptic and serotonin syndrome and the current use of monoamine 
oxidase inhibitors [17]. The North American Menopause Society (NAMS) suggests caution also in subjects affected by other conditions, such 
as bipolar disease, uncontrolled seizures, liver or kidney insufficiency, hypertension for SNRIs users or concurrent use of other SSRI or SNRI 
[16, 17].
All antidepressants need to be started at the lowest dose for 2 weeks and then the standard dose can be initiated. To stop the drug, in the 
same way, the lowest dose should be given for 2 weeks before ending the treatment. [16]
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Gabapentin and pregabalin
Gabapentin and pregabalin are anticonvulsant drugs able to decrease the frequency of HFs by binding to calcium channels located in the 
hypothalamus and, consequently, better modulating thermoregulatory activity [7, 28].
A beneficial effect of gabapentin on HFs was seen both in healthy menopausal women [29, 30] and in breast cancer survivors [31, 32] 
(Table 3).
Results from clinical studies performed in healthy menopausal women demonstrated a reduction of frequency and severity of HFs by around 
50% [29, 30]. 
Table 3. Main studies performed on gabapentin for HFs treatment.
Type of 
patients
Author, year of publica-
tion and type of study, 
number of patients (N)
Type of treatment Type of measurement Main results Adverse events (AEs)
Healthy 
women
Guttuso et al [29]
Randomised,  
double-blind,  
placebo-controlled trial
N = 59
1)  900 mg oral 
gabapentin for 
12 weeks versus 
placebo
2)  Extension phase: 
gabapentin up to 
2,700 mg/day
Diary for HFs severity 
and frequency, composite 
score including both
1)  45% HFs frequency and 
54% HFs score reduction 
from baseline, compared 
with 29% (p < 0.02) and 31% 
(p < 0.01), respectively, for 
placebo
2)  With the higher dose, further 
reduction of HFs (54% in HF 
frequency and 67% in the 
score)
-  Somnolence, dizziness, 
rash 
-  In 50% of gabapentin 
patients, at least one 
AE (versus 27.6% for 
placebo)
-  13% withdrawal rate in 
the gabapentin group 
for AEs (versus 3% for 
placebo)
Butt et al [30]
Randomised,  
double-blind,  
placebo-controlled trial
N = 200
900 mg
gabapentin for  
4 weeks
Diary for HFs severity and 
frequency, score including 
both
51% HFs score and 45.7% 
frequency reduction versus 
placebo (26.5% and 24.7%, 
respectively, p < 0.001)
More dizziness, 
unsteadiness
and drowsiness in the 
gabapentin group versus 
placebo in the first  
treatment week, with  
later AEs reduction
Breast 
cancer 
survivors
Pandya et al [31]
Randomised,  
double-blind,  
placebo-controlled,  
multi-institutional trial
N = 420 BCSs
300 mg/d or 900 
mg/d gabapentin 
versus placebo 
over 8
weeks
Diary for HFs severity, 
frequency and duration
44% HFs frequency and 46% 
severity reduction in the 900 
mg gabapentin group versus 
placebo (15% for both, p < 
0.0001) → gabapentin is effec-
tive in HFs control at a dose of 
900 mg/day
-  Withdrawal rate of 12% 
at 4 weeks and 17% at 8 
weeks for AEs
-  Significant worsening of 
appetite
Biglia et al [32] RCT
N = 115 BCSs
Oral gabapentin 
900 mg/day
(N = 60) versus 
vitamin E 800 IU/day 
(N = 55)
for 12 weeks 
1)  For HFs: daily HFs diary
2) For sleep quality: PSQI
3)  For other menopausal 
Symptoms: MRS
4)  For QoL: SF-36 Health 
Survey
1)  HFs frequency and score 
decreased by 57% and 67%, 
respectively, (p < 0.05) in the 
gabapentin group
2)  Improvement in quality  
of sleep (PSQI score  
reduction: 21.33%,  
p < 0.05).
The prescribed treatment 
with gabapentin was 
never started by 28.3%  
of BCSs and was  
interrupted by 28% of 
BCSs for AEs (dizziness 
and somnolence)
HFs = hot flushes; AEs: adverse events; BCSs = breast cancer survivors; PSQI = Pittsburgh Sleep Quality Index; MRS = Menopause Rating Scale;  
QoL = quality of life
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In breast cancer survivors, a 44%–57% decrease in HFs frequency and a 46%–67% decrease in HFs severity were reported with gabapentin 
in two studies on 420 and 115 breast cancer survivors, respectively [31, 32]. Furthermore, the quality of sleep improved with gabapentin 
900 mg/day in these women [32].
For breast cancer patients, a Cochrane review includes gabapentin among the effective drugs in reducing with a mild to moderate effect 
HFs [20]. Furthermore, gabapentin is included among the suggested recommendations for HFs relief in breast cancer survivors by ACS and 
ASCO [9].
Pregabalin (150 to 300 mg/day) is effective in HF relief but it is less studied than gabapentin [7]. However, compared to SSRIs/SNRIs, gaba-
pentin is as effective but has more side effects [6]. In a study on 115 breast cancer survivors using gabapentin 900 mg/day, 28.3% of the 
patients never started the treatment and a further 28% of them interrupted the treatment due to side effects [32].
The most common side effects on gabapentin are drowsiness, unsteadiness and dizziness [15, 30, 32], up to 50% in postmenopausal healthy 
women [29]. Consequently, withdrawal rates ranging from 12% to 17% are reported [29, 31]. NAMS alerts also for possible suicidal thoughts 
and behaviours with gabapentin and pregabalin [17].
Clonidine
Clonidine is an anti-hypertensive alpha-adrenergic agonist, which may inhibit flushing by reducing peripheral vascular reactivity [33]. How-
ever, the exact mechanism of action is still unclear. In a systematic review and meta-analysis on non-hormonal therapies for menopausal HFs 
[18], clonidine significantly reduced the frequency of HFs in four out of ten trials included.
For breast cancer patients, two placebo-controlled RCTs included in a Cochrane systematic review [21] showed a moderate reduction in the 
frequency and severity of HFs.
Furthermore, in the double-blind, placebo-controlled RCT by Boeckhout et al [25], clonidine 0.1 mg/day for 12 weeks significantly decreased 
by 26% HFs score in 28 breast cancer survivors (p < 0.045) compared to 17 patients who received placebo. In the same study, another group 
of 38 breast cancer patients employed venlafaxine and the decline in HFs score was faster with venlafaxine than with clonidine.
However, significant side effects (xerostomia, dizziness, constipation, hypotension and potential hypertension, if suddenly interrupted) have 
been often reported with clonidine [17, 18] and, due to safety problems, its clinical use is poor.
Purified pollen extract
Purified pollen extract (PPE) is a supplement sourced from pure pollen extract green climacteric (GC Fem). It is a combination of pollen and 
pistil extracts (PI 82), from plants of the Poaceae family, and vitamin E. The pollen and pistil extracts have high antioxidant enzyme superoxide 
dismutase activity [34]. Each tablet contains 40 mg of GC Fem, 120 mg of PI 82 and 5 mg of vitamin E. 
Beneficial effects of PPE on vasomotor symptoms may derive from the inhibition of serotonin uptake at the synaptosomal junction, with an 
SSRI ‘like’ mode of action [34]. PPE does not contain any of the common phytoestrogens and does not show uterotropic-oestrogenic effects 
[34, 35].
Furthermore, the production technology which allows the elimination of potential allergens from PPE ensures patient safety, without any 
contraindications of its use in patients with pollen allergy [34].
PPE has proven clinical efficacy in the treatment of menopausal symptoms like HFs and insomnia in healthy women. A double-blind, placebo-
controlled RCT on 64 postmenopausal symptomatic women showed that PPE is effective in HF treatment [34]. In the PPE group, a 65% 
reduction in HFs was observed, compared to 38% in the placebo group (p < 0.006). PPE also showed positive effects on other quality of life-
related symptoms, such as dizziness, mood swings and tiredness, which often accompany vasomotor symptoms.
No data are available for PPE in women with breast cancer, but the lack of oestrogenic effect demonstrated in a preclinical study by Hellstrom 
et al [35] suggests that PPE can be a suitable option. In this study, PPE was found to contain low, subeffective concentrations of daidzin, 
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daidzein and genistin at high-performance liquid chromatography. Genistein, formononetin and biochanin could not be detected. Moreover, 
PPE was tested in the same study for oestrogenic activity in the immature female rat uterotrophic bioassay and no uterine growth was seen 
with PPE in the high dose of 500 mg kg/day. 
Moreover, in a recent in vitro study, PPE was neutral in the cell lines alone or in combination with oestradiol or growth factors in terms of cell 
proliferation and cell apoptosis, both in cells transfected with the progesterone receptor membrane component-1 (PGRMC1) or not. This is 
important safety data since recent experimental data revealed that oestrogens could trigger a further proliferative effect on breast cancer 
cells via PGRMC1, in addition to the proliferative effect via intracellularly located receptors [36].
In the clinical study by Winther et al [34], which employed PPE 2/day per 3 months, the evaluation of vaginal dryness and menstrual bleeding 
showed no change during PPE treatment. Moreover, serum measurements of the follicle stimulating hormone (FSH), E2, testosterone and 
sex hormone-binding globulin before and after the study period did not suggest any hormone effect of PPE. 
Furthermore, an in vitro study demonstrated that PPE does not inhibit the CYP2D6 enzyme and thus does not interfere with tamoxifen 
metabolism [37]. 
Available data on the safety and efficacy of PPE are shown in Table 4.
Black cohosh
Native American women have used the extract of black cohosh (Actae racemosa or Cimicifugae racemosae) for centuries as a phytotherapic 
cure for many different conditions. Nowadays, black cohosh is indicated only for the management of climacteric symptoms [38].
The mechanism underlying the bioactivity of black cohosh is still unclear. Selective modulation of oestrogen receptors (SERM), serotonin 
partial agonist mechanism, antioxidant and anti-inflammatory effects have been suggested [38, 39]. Initial studies using in vitro and in vivo 
assays suggested oestrogenic activity but these data have not been confirmed subsequently [38, 40].
Moreover, more recent different clinical trials showing no effect on the vaginal or endometrial thickness or on sexual hormones variation 
confirmed the lack of oestrogenic activity [38, 41, 42].
In the Herbal Alternatives for Menopause (HALT) double-blind, placebo-controlled RCT on 351 patients, black cohosh given up to 52 weeks 
determined no effects on vaginal epithelium, endometrium or sexual hormones [41].
In a large prospective open study on 400 postmenopausal women, the endometrial safety of black cohosh was assessed before and after 
52 weeks of treatment, showing no increase in endometrial thickness on ultrasound and no case of endometrial hyperplasia or of serious 
adverse endometrial outcome [42]. 
RCTs showed HF reduction in healthy menopausal women and in breast cancer survivors [38]. However, a Cochrane systematic review of 
16 RCTs, on 2,027 symptomatic menopausal women [43], did not show a significant difference between black cohosh and placebo in the 
frequency of HFs, concluding that there is insufficient evidence to support the use of black cohosh for controlling menopausal symptoms. 
The inconsistency of the evidence may be explained also by the heterogeneity of results among the studies due to the use of different parts 
of the plant or different kind of extract of black cohosh. In the review, at least five different oral preparations of black cohosh were included.
Another recent systematic review and meta-analysis, considering four RCTs on black cohosh, confirmed this data, showing that overall black 
cohosh was not associated with changes in the rate of HFs [44].
As regards side effects, suspected hepatotoxicity was previously reported, but a meta-analysis of five randomised, double-blind, controlled 
clinical trials on 1,020 women showed no evidence that black cohosh has any adverse effect on liver function [45]. 
The use of black cohosh in breast cancer patients is still controversial due to its SERM–like mechanism of action [46]. In vitro studies in 
MCF-7 cells during chronic use of black cohosh show that changes in the gene expression pattern are more similar to tamoxifen than to oes-
tradiol [47]. In animal models, black cohosh given to rats for 40 weeks determines a dose-dependent reduction of breast cancer, suggesting 
a chemopreventive potential [48]. 
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Table 4. PPE for HFs treatment.
Author, year of 
publication and 
type of study
Number of pa-
tients (N) and type 
of treatment
Type of 
measurement Main results
Efficacy
in healthy 
women
Winther et al [34]
Double-blind, 
placebo-controlled 
trial
N = 64
PPE 2/day per 3 
months
- MRS
- 15 QoL parameters
-  65% HFs reduction in the PPE 
group versus 38% in the placebo 
group (p < 0.006)
-  Improvement in the QoL parameters 
(tiredness, dizziness, mood, libido, 
headache, irritability, mood swings 
and sensitiveness) in the PPE group 
compared to baseline (p < 0.031)
Safety in 
breast cancer 
survivors
No oestrogenic 
activity
Hellstrom et al [35]
In vitro study
-  High-performance liquid 
chromatography analyses of 
phytoestrogens in PPE 
-  Oestrogenic activity evalua-
tion in the immature female rat 
uterotrophic bioassay with PPE 
-  PPE in the high dose of 500 mg 
kg/day contains low, subeffective 
concentrations of daidzin, daidzein 
and genistin. Genistein, formonone-
tin and biochanin could not be 
detected. 
-  No uterine growth in female rats 
with PPE
Seeger et al [36]
In vitro study
-  MCF-7 and T47D cells were 
transfected with PGRMC1
-  Different concentrations of PPE 
alone and in combination with 
E2 or growth factor were tested
-  Proliferation was determined by 
the MTT test
-  Apoptosis was determined by 
CDD ELISA kit 
PPE was neutral in the cell lines alone 
or in combination with E2 or growth 
factors in terms of cell proliferation 
and cell apoptosis, both in cells trans-
fected with PGRMC1 or not
Winther et al [34]
Double-blind, 
placebo-controlled 
trial
N = 64
PPE 2/day per 3 
months
- 15 QoL parameters
- Diary of AUB 
-  Blood samples for FSH, E2, TT, 
SHBG
-  No changes in vaginal dryness 
parameter
- No AUB
-  No change in blood levels of FSH, 
E2, TT, SHBG
No interference 
with CYP2D6 
enzyme
Goldstein et al [37]
In vitro study
Test for potential inhibition of 
CYP2D6 enzyme by PPE at high 
concentrations in pooled human 
liver microsome with Quinidine as 
a reference. 
Negligible inhibition of CYP2D6 with 
PPE (6.53% to 10.67%), whereas 
Quinidine completely inhibited the 
CYP2D6.
PPE = Purified pollen extract; MRS = Menopause Rating Scale; HFs = hot flushes; QoL = quality of life; PGRMC1 = progesterone receptor membrane com-
ponent-1; MTT test = 3−(4,5-dimethylthiazol-2-yl) 2,5-diphenyl-tetrazolium bromide test; CDD = Cell death detection; FSH = follicle stimulating hormone; 
E2 = estradiol; TT = testosterone; SHBG = hormone-binding globulin; AUB = abnormal uterine bleeding; ELISA = enzyme-linked immunoassay
Furthermore, since breast density is a biomarker for breast cancer risk, different studies showed no significant modification in mammary 
breast density while using black cohosh [42, 49, 50]. In the 52-weeks study by Raus et al [42] on 400 postmenopausal women, increase in 
breast density was observed only in one patient who developed an invasive breast cancer unrelated to black cohosh use [49, 50]. In a pro-
spective study on 74 postmenopausal patients, Hirschberg et al [49] observed no increase in breast density, assessed by mammography, and 
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of breast cancer proliferation by Ki 67 determination through agobiopsy, both performed at baseline and after 24 weeks of black cohosh 
use. In the comparative study of Lundström et al [50] on 65 postmenopausal patients using black cohosh and 154 under HRT (oestradiol 2 
mg/norethisterone acetate or tibolone) or placebo, breast density assessed by mammography performed at baseline and after 24 weeks was 
significantly increased with HRT use but not with placebo or black cohosh. 
Only few RCTs have been performed in order to understand the use and safety of black cohosh in breast cancer patients. In the RCT by Jacobson 
et al [51], 85 breast cancer survivors, most of whom were on tamoxifen, were assigned to black cohosh or placebo. No significant differences 
were seen in HFs frequency and intensity with both treatments; however, in the black cohosh group, a significant improvement in sweating was 
observed. Interestingly, changes in blood levels of FSH and luteinizing hormone (LH) did not differ between the placebo and the black cohosh 
group. The RCT by Pockaj et al [52] failed to provide any evidence that black cohosh 40 mg/day reduces HFs more than the placebo (mean decrease 
in HFs score: 20% in the black cohosh group versus 27% in the placebo group, p = 0.53). Results from the only available RCTs performed in breast 
cancer patients show that there is currently a lack of evidence to support the use of black cohosh for HFs relief in breast cancer survivors [38, 53]. 
An observational, retrospective, cohort study on 18,861 breast cancer survivors, 1,102 of which receiving black cohosh, analysing diseases-free 
survival after breast cancer, showed no detrimental effect on recurrence rate [54]. 
Regarding tamoxifen users, a potential in vitro inhibition of CYP2D6 has been described, but clinical data suggest that the interaction of black 
cohosh with tamoxifen is unlikely [38].
Although black cohosh seems to have a good safety profile, more high-quality studies are needed to reach a definitive conclusion regarding 
its efficacy on HFs [43, 44, 46].
A summary of the evidence on the efficacy and safety of black cohosh on HFs relief is described in Table 5.
Oxybutinin
Studies suggest that oxybutynin, an anticholinergic generally employed for urinary incontinence due to overactive bladder, is an effective 
treatment for HFs, both in healthy women [55] and in breast cancer survivors [56].
Weight loss
Data from the WHI trial in healthy women show that weight loss determines a reduction in HFs [57]. Two RCTs confirm these findings, sug-
gesting that weight loss is associated in overweight or obese healthy women with a reduction in HFs [58, 59]. In breast cancer survivors, 
prevention of weight gain after diagnosis can help in controlling HFs, whereas the role of intentional weight loss after diagnosis on vasomotor 
symptoms is still not defined [60].
Table 5. Black cohosh for HFs treatment.
Black cohosh versus placebo Outcome
HFs frequency and intensity - No statistically significant difference in systematic reviews and meta-analysis [43, 44] 
- Same results in RCTs in BCSs [51, 52]
Night sweats frequency - No statistically significant difference in systematic reviews and meta-analysis [43, 44]
- In an RCT in BCSs significant improvement [51]
Menopausal symptom score 
(KI, GCS and MRS)
No statistically significant difference in systematic reviews and meta-analysis [43, 44]
Safety profile - Good safety profile in the general population [38, 45]
- No endometrial thickness increase [41, 42]
- No detrimental effect on recurrence rate in BCSs [54] and unlikely interaction with tamoxifen [38]
KI = Kupperman Index; GCS = Green Climacteric Scale; MRS = menopause rating scale; RCT = randomised controlled trial; BCSs = breast cancer survivors 
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Yoga and exercise
A Cochrane review failed to demonstrate a positive effect of exercise and yoga on HFs [61]. However, a recent study reported that exercise 
training may decrease the severity of HFs [62] and in an RCT by Cramer et al [63], yoga was effective in reducing vasomotor symptoms in 
breast cancer survivors.
In a systematic review and meta-analysis of 13 RCTs on 1,306 women, yoga compared with no treatment reduced total menopausal symp-
toms, HFs, psychological and urogenital symptoms without serious adverse events [64]
Cognitive behavioural therapy
Cognitive behavioural therapy (CBT) is, among mind-body techniques, an effective treatment for HFs both for healthy postmenopausal 
women and breast cancer survivors [17]. In the MENOS 2 trial, an RCT conducted on 140 healthy postmenopausal women, CBT significantly 
reduced vasomotor symptoms [65]. The MENOS 1 trial was an RCT specifically addressed to breast cancer patients in which CBT significantly 
reduced HFs after 9 weeks compared with usual care. The improvement was maintained at 26 weeks from randomisation and additional 
benefits to mood, sleep and quality of life were observed [66].
Relaxation therapy
For breast cancer patients, a Cochrane Review assessed that relaxation therapy has a mild to moderate effect in reducing HFs [21]. Neverthe-
less, in healthy perimenopausal and postmenopausal women, a more recent Cochrane review concluded that evidence is insufficient to prove 
the effectiveness of relaxation techniques [67]. 
Acupuncture
Acupuncture has been shown to reduce HFs in healthy women, compared with no treatment [68].
A meta-analysis including three systematic reviews and four RCTs assessed the effectiveness of acupuncture in reducing HF frequency and 
severity in peri or postmenopausal women, with improvement also in health-related quality of life items and without significant side effects 
[69].
However, in breast cancer patients, a Cochrane Review failed to confirm its effectiveness in reducing HFs [21]. Further data are needed to 
prove a positive effect of acupuncture and, eventually, to predict which subset of patients could benefit from it.
Cooling strategies
Moreover, since temperature is a trigger of flushing, cooling strategies have also been proposed in order to reduce HFs (dressing in layers, 
with light, cotton clothing and standing away from sources of warming); however, the efficacy of such strategies is not supported by scientific 
evidence [17].
Stellate ganglion block
Stellate ganglion block (SGB), consisting of a vertebral cervical block by local anaesthetic injection, has been proposed for HF treatment. It 
was suggested that SGB resets the temperature-regulating mechanisms by interrupting the connections between the central and sympa-
thetic nervous system. Only one RCT on 40 postmenopausal women focussed on SGB for HFs [70], showing no significant difference in the 
overall HF frequency after SGB, while four open-label studies showed a 45%–90% reduction in HFs with SGB [7]. Larger RCTs are needed 
in order to evaluate its efficacy. Even if it is reported that SGB performed by skilled practitioners is safe [70], concerns related to the close 
proximity of critical structures may hinder the spread of this non-hormonal option for non-HF relief. 
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Conclusion
In menopausal women, vasomotor symptoms, and in particular, HFs, frequently remain underdiagnosed and undertreated, with a negative 
impact on the patient’s quality of life. Paying more attention to the needs and preferences of menopausal women may reduce the num-
ber of untreated cases of HFs. Psychoactive agents are commonly used to treat HFs in some countries, such as the USA but are less well 
accepted by physicians and patients in others. Whatever the perception toward these drugs is, they are mostly used as off-label drugs and 
for short periods. On the other hand, CAM approaches have provided interesting data in recent studies. Among them, PPE has a confirmed 
non-oestrogenic effect and has been shown to be effective in decreasing HFs, night sweats, irritability and improving the quality of sleep in 
menopausal women, with consequent improvement in the quality of life. Black cohosh is a well-known traditional medicine treatment, which 
is widely used in spite of the inconsistency of data collected so far requiring further research. Recent evidence supports a positive role of 
physical activity in the management of HFs. 
In order to manage HFs in menopausal women effectively, clinicians should identify the patient’s health profile and personal preferences and 
then select an individualised and safe therapy.
Research agenda
Future research on the molecular mechanisms of flushing during menopause and on the effects of available and novel treatments will further 
improve the management of HFs in both healthy menopausal women and in women with contraindications to oestrogens.
Since limitations of the available evidence are in particular the imprecision or lack in the data and in the study method details, a great effort 
must be made to perform RCTs with large samples and with a strict methodology to allow comparison of the different strategies.
Acknowledgments
The authors thank Editamed srl, Tommaso Sacco M.D. for medical writing services and Raquel Carvalhosa, Ph.D. for editorial services. 
Conflicts of interest
Anna Maria Paoletti, Francesco De Seta and Stefano Lello declare no conflict of interests. Nicoletta Biglia had a financial relationship (lecturer, 
member of advisory boards and/or consultant) with Gedeon Richter, Shionogi Limited and Italfarmaco. Rossella E Nappi has a financial rela-
tionship (lecturer, member of advisory boards and/or consultant) with Bayer HealthCare, Endoceutics, Gedeon Richter, HRA Pharma, MSD, 
Novo Nordisk, Pfizer, Shionogi and Teva. Valentina E Bounous had a financial relationship with Italfarmaco S.p.A. (medical writing) and has a 
financial relationship with Shionogi (medical writing, tables preparation).
Funding
Financial support for medical writing (table preparation) and editorial services (English supervision) was provided by Shionogi.
References
 1. Blümel JE, Chedraui P, and Baron G, et al (2011) Collaborative group for research of the climacteric in Latin America (REDLINC), a large 
multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women Menopause 18 
778–785 https://doi.org/10.1097/gme.0b013e318207851d
 2. Freeman EW and Sherif K (2007) Prevalence of hot flushes and night sweats around the world: a systematic review Climacteric 10 
197–214 https://doi.org/10.1080/13697130601181486 PMID: 17487647
Re
vi
ew
ecancer 2019, 13:909; www.ecancer.org; DOI: https://doi.org/10.3332/ecancer.2019.909  12
 3. Avis NE, Crawford SL, and Greendale G, et al (2015) Study of women’s health across the nation (SWAN), study of women’s health across 
the nation, duration of menopausal vasomotor symptoms over the menopause transition JAMA Intern Med 175 531–539 https://doi.
org/10.1001/jamainternmed.2014.8063 PMID: 25686030 PMCID: 4433164
 4. Hunter M, Gentry-Maharaj A, and Ryan A, et al (2012) Prevalence, frequency and problem rating of hot flushes persist in older post-
menopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional 
cohort study of 10 418 British women aged 54–65: Prevalence, frequency and problem rating of hot flushes BJOG 119 40–50 https://
doi.org/10.1111/j.1471-0528.2011.03166.x
 5. Constantine GD, Graham S, and Clerinx C, et al (2016) Behaviours and attitudes influencing treatment decisions for menopausal 
symptoms in five European countries Post Reprod Health 22 112–122 https://doi.org/10.1177/2053369116632439 PMID: 26895640 
PMCID: 5019289
 6. Baber RJ, Panay N, and Fenton AT, et al, (2016) IMS Recommendations on women’s midlife health and menopause hormone therapy 
Climacteric 19(2) 109–150 https://doi.org/10.3109/13697137.2015.1129166 PMID: 26872610
 7. Knobf MT (2006) The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors 
Oncologist 11 96–110 https://doi.org/10.1634/theoncologist.11-2-96 PMID: 16476831
 8. Curigliano G, Burstein HJ, and Winer EP, et al (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gal-
len international expert consensus conference on the primary therapy of early breast cancer 2017 Ann Oncol 28 1700–1712 https://
doi.org/10.1093/annonc/mdx308 PMID: 28838210 PMCID: 6246241
 9. Runowicz CD, Leach CR, and Henry NL, et al (2016) American cancer society/American society of clinical oncology breast cancer sur-
vivorship care guideline J Clin Oncol 34(6) 611–635 https://doi.org/10.1200/JCO.2015.64.3809
 10. Chlebowski RT, Hendrix SL, and Langer RD, et al (2003) WHI investigators, influence of estrogen plus progestin on breast cancer and 
mammography in healthy postmenopausal women: the women’s health initiative randomized trial JAMA 289(24) 3243–3253 https://
doi.org/10.1001/jama.289.24.3243 PMID: 12824205
 11. Bair YA, Gold EB, and Zhang G, et al (2008) Use of complementary and alternative medicine during the menopause transition: longitudi-
nal results from the study of women’s health across the nation Menopause 15 32–43 https://doi.org/10.1097/gme.0b013e31813429d6
 12. Posadzki P, Lee MS, and Moon TW, et al (2013) Prevalence of complementary and alternative medicine (CAM) use by menopausal 
women: a systematic review of surveys Maturitas 75 34–43 https://doi.org/10.1016/j.maturitas.2013.02.005 PMID: 23497959
 13. Peng W, Adams J, and Sibbritt DW, et al (2013) Critical review of complementary and alternative medicine use in menopause: 
focus on prevalence, motivation, decision-making, and communication Menopause 21(5) 536–548 https://doi.org/10.1097/
GME.0b013e3182a46a3e PMID: 24104604
 14. Tonob D and Melby MK (2017) Broadening our perspectives on complementary and alternative medicine for menopause: a narrative 
review Maturitas 99 79–85 https://doi.org/10.1016/j.maturitas.2017.01.013 PMID: 28364873
 15. American College of Obstetricians and Gynaecologists (2014) ACOG practice bulletin No. 141: management of menopausal symptoms 
Obstet Gynecol 123(1) 202–216 https://doi.org/10.1097/01.AOG.0000441353.20693.78 PMID: 24463691
 16. Handley AP and Williams M (2015) The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal 
women: a systematic review J Am Assoc Nurse Pract 27 54–61
 17. North American Menopause Society (NAMS) (2015) Nonhormonal management of menopause-associated vasomotor symp-
toms: 2015 position statement of The North American Menopause Society Menopause 22 1155–1174 https://doi.org/10.1097/
GME.0000000000000546 PMID: 26382310
 18. Nelson D, Vesco KK, and Haney E, et al (2006) Nonhormonal therapies for menopausal hot flashes: systematic review and meta-anal-
ysis JAMA 295 2057–2071 https://doi.org/10.1001/jama.295.17.2057 PMID: 16670414
Re
vi
ew
ecancer 2019, 13:909; www.ecancer.org; DOI: https://doi.org/10.3332/ecancer.2019.909  13
 19. Vilar-González S, Pérez-Rozos A, and Cabanillas-Farpón R, Mechanism of hot flashes Clin Transl Oncol 13(3) 143–147 PMID: 21421458
 20. Orleans RJ, Li L, and Kim MJ, et al (2014) FDA approval of paroxetine for menopausal hot flushes N Engl J Med 370(19) 1777–1779 
https://doi.org/10.1056/NEJMp1402080 PMID: 24806158
 21. Rada G, Capurro D, and Pantoja T, et al (2010) Non-hormonal interventions for hot flushes in women with a history of breast cancer 
Cochrane Database Syst Rev (9) CD004923 PMID: 20824841
 22. Loprinzi CL, Sloan JA, and Perez EA, et al (2002) Phase III evaluation of fluoxetine for treatment of hot flashes J Clin Oncol 20(6) 1578–
1583 https://doi.org/10.1200/JCO.2002.20.6.1578 PMID: 11896107
 23. Stearns V, Slack R, and Greep N, et al (2005) Paroxetine is an effective treatment for hot flashes: results from a prospective randomized 
clinical trial J Clin Oncol 23(28) 6919–6930 https://doi.org/10.1200/JCO.2005.10.081 PMID: 16192581
 24. Loprinzi CL, Kugler JW, and Sloan JA, et al (2000) Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised 
controlled trial Lancet 356(9247) 2059–2063 https://doi.org/10.1016/S0140-6736(00)03403-6
 25. Boekhout AH, Vincent AD, and Dalesio OB, et al (2011) Management of hot flashes in patients who have breast cancer with venla-
faxine and clonidine: a randomized, double-blind, placebo-controlled trial J Clin Oncol 29(29) 3862–3868 https://doi.org/10.1200/
JCO.2010.33.1298 PMID: 21911720
 26. Aguglia E, Ravasio R, and Simonetti M, et al (2012) Use and treatment modalities for SSRI and SNRI antidepressants in Italy during the 
period 2003–2009, Curr Med Res Opin 28(9) 1475–1484 https://doi.org/10.1185/03007995.2012.713341 PMID: 22809113
 27. Wu EQ, Greenberg PE, and Yang E, et al (2009) Treatment persistence, healthcare utilisation and costs in adult patients with 
major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs J Med Econom 12 124–135 https://doi.
org/10.3111/13696990903093537
 28. Hayes LP, Carroll DG, and Kelley KW (2011) Use of gabapentin for the management of natural or surgical menopausal hot flashes Ann 
Pharmacother 45 388–394 https://doi.org/10.1345/aph.1P366 PMID: 21343402
 29. Guttuso TJ Jr, Kurlan R, and McDermott MP, et al (2003) Gabapentin’s effects on hot flashes in postmenopausal women: a randomized 
controlled trial Obstet Gynecol 101 337–345 PMID: 12576259
 30. Butt DA, Lock M, and Lewis JE, et al (2008) Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial 
Menopause 15 310–318 https://doi.org/10.1097/gme.0b013e3180dca175
 31. Pandya KJ, Morrow GR, and Roscoe JA, et al (2005) Gabapentin for hot flashes in 420 women with breast cancer: a randomised dou-
ble-blind placebo-controlled trial Lancet 366 818–824 https://doi.org/10.1016/S0140-6736(05)67215-7 PMID: 16139656 PMCID: 
1627210
 32. Biglia N, Sgandurra P, and Peano E, et al (2009) Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin versus 
vitamin E Climacteric J Int Menopause Soc 12 310–318 https://doi.org/10.1080/13697130902736921
 33. Sassarini J, Fox H, and Ferrell W, et al (2012) Hot flushes, vascular reactivity and the role of the α-adrenergic system Climacteric 15 
332–338 https://doi.org/10.3109/13697137.2011.636847 PMID: 22208784
 34. Winther K, Rein E, and Hedman C (2005) Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves 
quality of life in menopausal women: a randomized, placebo-controlled, parallel study Climacteric 8 162–170 https://doi.
org/10.1080/13697130500117987 PMID: 16096172
 35. Hellström AC and Muntzing J (2012) The pollen extract femal-a nonestrogenic alternative to hormone therapy in women with meno-
pausal symptoms Menopause 19 825–829 https://doi.org/10.1097/gme.0b013e31824017bc
 36. Seeger H, Ruan X, and Neubauer H, et al (2017) Membrane-initiated effects of serelys® on proliferation and apoptosis of human breast 
cancer cells Gynecol Endocrinol 34(4) 353–356 https://doi.org/10.1080/09513590.2017.1407751
Re
vi
ew
ecancer 2019, 13:909; www.ecancer.org; DOI: https://doi.org/10.3332/ecancer.2019.909  14
 37. Goldstein SR, Espié M, and Druckmann R (2015) Does purified Swedish pollen extract, a nonhormonal treatment for vasomotor symp-
toms, inhibit the CYP2D6 enzyme system? Menopause 22 1212–1214 https://doi.org/10.1097/GME.0000000000000535 PMID: 
26325084
 38. Drewe J, Bucher KA, and Zahner C (2015) A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and 
cancer patients SpringerPlus 4 65 https://doi.org/10.1186/s40064-015-0808-y PMID: 25713759 PMCID: 4331402
 39. Ruhlen RL, Sun GY, and Sauter ER (2008) Black cohosh: insights into its mechanism(s) of action Integr Med Insights 3 21–32 https://doi.
org/10.4137/117863370800300002 PMID: 21614156 PMCID: 3046019
 40. Jarry H, Metten M, and Spengler B, et al (2003) In vitro effects of the Cimicifuga racemosa extract BNO 1055 Maturitas 44(1) S31–S38 
https://doi.org/10.1016/S0378-5122(02)00346-8 PMID: 12609557
 41. Reed SD, Newton KM, and LaCroix AZ, et al (2008) Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-
controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the herbal alternatives for menopause 
(HALT) study Menopause 15(1) 51–58 PMID: 18257142
 42. Raus K, Brucker C, and Gorkow C, et al (2006) First-time proof of endometrial safety of the special black cohosh extract (Actaea or 
Cimicifuga racemosa extract) CR BNO 1055 Menopause 13 678–691 https://doi.org/10.1097/01.gme.0000196813.34247.e2 PMID: 
16837890
 43. Leach MJ and Moore V (2012) Black cohosh (Cimicifuga spp.) for menopausal symptoms Cochrane Database Syst Rev 9 CD007244
 44. Franco OH, Chowdhury R, and Troup J, et al (2016) Use of plant-based therapies and menopausal symptoms: a systematic review and 
meta-analysis JAMA 315 2554–2563 https://doi.org/10.1001/jama.2016.8012 PMID: 27327802
 45. Naser B, Schnitker J, and Minkin MJ, et al (2011) Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of ran-
domized controlled clinical trials for isopropanolic black cohosh extract Menopause 18(4) 366–375 https://doi.org/10.1097/
gme.0b013e3181fcb2a6 PMID: 21228727
 46. Fritz H, Seely D, and McGowan J, et al (2014) Black cohosh and breast cancer: a systematic review Integr Cancer Ther 13 12–29 https://
doi.org/10.1177/1534735413477191
 47. Gaube F, Wolfl S, and Pusch L, et al (2007) Gene expression profiling reveals effects of cimicifuga racemosa (L.) NUTT. (black cohosh) 
on the estrogen receptor positive human breast cancer cell line MCF-7 BMC Pharmacol 7 11 https://doi.org/10.1186/1471-2210-7-11 
PMID: 17880733 PMCID: 2194763
 48. Einbond LS, Soffritti M, and Degli Esposti D, et al (2012) Chemopreventive potential of black cohosh on breast cancer in Sprague–Daw-
ley rats Anticancer Res 32(1) 21–30 PMID: 22213284
 49. Hirschberg AL, Edlund M, Svane G, et al (2007) An isopropanolic extract of black cohosh does not increase mammographic breast density 
or breast cell proliferation in postmenopausal women Menopause 14(1) 89–96 https://doi.org/10.1097/01.gme.0000230346.20992.34
 50. Lundström E, Hirschberg AL, and Söderqvist G (2011) Digitized assessment of mammographic breast density–effects of continuous 
combined hormone therapy, tibolone and black cohosh compared to placebo Maturitas 70(4) 361–364 https://doi.org/10.1016/j.
maturitas.2011.08.009 PMID: 21958943
 51. Jacobson JS, Troxel AB, and Evans J, et al (2001) Randomized trial of black cohosh for the treatment of hot flashes among women with 
a history of breast cancer J Clin Oncol 19(10) 2739–2745 https://doi.org/10.1200/JCO.2001.19.10.2739 PMID: 11352967
 52. Pockaj BA, Gallagher JG, and Loprinzi CL, et al (2006) Phase III double-blind, randomized, placebo-controlled crossover trial of 
black cohosh in the management of hot flashes: NCCTG Trial N01CC1 J Clin Oncol 24(18) 2836–2841 https://doi.org/10.1200/
JCO.2005.05.4296 PMID: 16782922
Re
vi
ew
ecancer 2019, 13:909; www.ecancer.org; DOI: https://doi.org/10.3332/ecancer.2019.909  15
 53. National Institute for Care and Health Excellence (NICE) (2017) Early and locally advanced breast cancer: diagnosis and treatment Clini-
cal guideline [nice.org.uk/guidance/cg80] Date accessed: 24/2/2019
 54. Henneicke-von Zepelin HH, Meden H, and Kostev K, et al (2007) Isopropanolic black cohosh extract and recurrence-free survival after 
breast cancer Int J Clin Pharmacol Ther 45(3) 143–154 https://doi.org/10.5414/CPP45143 PMID: 17416109
 55. Simon JA, Gaines T, and LaGuardia KD (2016) Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized 
clinical trial Menopause 23(11) 1214–1221 https://doi.org/10.1097/GME.0000000000000773 PMID: 27760081
 56. San Antonio Breast Cancer Symposium (SABCS) (2018) ‘It’s Going to Be a Useful Agent’: Oxybutynin for Hot Flashes Medscape  10 Dec 
10 2018 (Abstract GS6-02, presented 7 December 2018)
 57. Kroenke CH, Caan BJ, and Stefanick ML, et al (2012) Effects of a dietary intervention and weight change on VMS in the women’s health 
initiative Menopause 19 980–988 https://doi.org/10.1097/gme.0b013e31824f606e PMID: 22781782 PMCID: 3428489
 58. Thurston RC, Ewing LJ, and Low CA, et al (2015) Behavioral weight loss for the management of menopausal hot flashes: a pilot study 
Menopause 22 59–65 https://doi.org/10.1097/GME.0000000000000274
 59. Huang AJ, Subak LL, and Wing R, et al (2010) An intensive behavioral weight loss intervention and hot flushes inwomen Arch Intern Med 
170 1161–1167 https://doi.org/10.1001/archinternmed.2010.162 PMID: 20625026 PMCID: 3030922
 60. Caan BJ, Emond JA, and Su HI, et al (2012) Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer 
survivors J Clin Oncol 30 1492–1497 https://doi.org/10.1200/JCO.2011.36.8597 PMID: 22430275 PMCID: 4874147
 61. Daley A, Stokes-Lampard H, and Thomas A, et al (2014) Exercise for vasomotor menopausal symptoms Cochrane Database Syst Rev (11) 
CD006108 PMID: 25431132
 62. Bailey TG, Cable NT, and Aziz N, et al (2016) Exercise training reduces the acute physiological severity of post-menopausal hot flushes 
J Physiol 594 657–667 https://doi.org/10.1113/JP271456
 63. Cramer H, Rabsilber S, and Lauche R, et al (2015) Yoga and meditation for menopausal symptoms in breast cancer survivors-A random-
ized controlled trial Cancer 13 2175–2184 https://doi.org/10.1002/cncr.29330
 64. Cramer H, Peng W, and Lauche R (2018) Yoga for menopausal symptoms-A systematic review and meta-analysis Maturitas 109 13–25 
https://doi.org/10.1016/j.maturitas.2017.12.005 PMID: 29452777
 65. Ayers B, Smith M, and Hellier J, et al (2012) Effectiveness of group and self-help cognitive behavior therapy in reducing problematic 
menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial Menopause 19 749–759 https://doi.org/10.1097/
gme.0b013e31823fe835 PMID: 22336748
 66. Mann E, Smith MJ, and Hellier J, et al (2012) Cognitive behavioural treatment for women who have menopausal symptoms after breast 
cancer treatment (MENOS 1): a randomised controlled trial Lancet Oncol 13 309–318 https://doi.org/10.1016/S1470-2045(11)70364-3 
PMID: 22340966 PMCID: 3314999
 67. Saensak S, Vutyavanich T, and Somboonporn W, et al (2014) Relaxation for perimenopausal and postmenopausal symptoms Cochrane 
Database Syst Rev 7 CD008582
 68. Dodin S, Blanchet C, and Marc I, et al (2013) Acupuncture for menopausal hot flushes ed The Cochrane Collaboration, Cochrane Database 
Systematic Reviews (Chichester, UK: John Wiley & Sons Ltd) [http://doi.wiley.com/10.1002/14651858.CD007410.pub2] 
 69. Befus D, Coeytaux RR, and Goldstein KM, et al (2018) Management of menopause symptoms with acupuncture: an umbrella system-
atic review and meta-analysis J Altern Complement Med 4 314–323 https://doi.org/10.1089/acm.2016.0408
 70. Walega DR, Rubvvbounoussin LH, and Banuvar S, et al (2014) Effects of stellate ganglion block on vasomotor symptoms: find-
ings from a randomized controlled clinical trial in postmenopausal women Menopause 21(8) 807–814 https://doi.org/10.1097/
GME.0000000000000194 PMID: 24496086 PMCID: 4110158
